US2017114039A1PendingUtilityA1

Inhibitors of bruton's tyrosine kinase

Assignee: BIOGEN MA INCPriority: Jun 8, 2012Filed: May 27, 2016Published: Apr 27, 2017
Est. expiryJun 8, 2032(~5.9 yrs left)· nominal 20-yr term from priority
C07D 207/16C07D 207/28C07D 211/56C07D 401/04C07D 401/14C07B 2200/13
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides a compound, solid forms, and compositions thereof, which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same. The present invention also provides methods of making provided compound and solid forms.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 - 40 . (canceled) 
     
     
         41 . A solid form of Compound I: 
       
         
           
           
               
               
           
         
         wherein the solid form is amorphous or crystalline. 
       
     
     
         42 . A method of treating a disorder selected from the group consisting of rheumatoid arthritis, lupus erythematosus, atopic dermatitis, leukemia and lymphoma comprising administering to a subject an effective amount of the solid form of  claim 41 . 
     
     
         43 . The method of  claim 42 , wherein the disorder is rheumatoid arthritis. 
     
     
         44 . The method of  claim 42 , wherein the disorder is systemic lupus erythematosus. 
     
     
         45 . The method of  claim 42 , wherein the disorder is atopic dermatitis. 
     
     
         46 . The method of  claim 42 , wherein the disorder is leukemia or lymphoma. 
     
     
         47 . A compound selected from the group consisting of 
       
         
           
           
               
               
           
         
         wherein —OR LG  is a suitable leaving group; and 
         PG is a suitable protecting group. 
       
     
     
         48 . The compound of  claim 47  wherein the compound is: 
       
         
           
           
               
               
           
         
         wherein —OR LG  is a suitable leaving group. 
       
     
     
         49 . The compound of  claim 47  wherein the compound is: 
       
         
           
           
               
               
           
         
         wherein —OR LG  is a suitable leaving group. 
       
     
     
         50 . The compound of  claim 47  wherein the compound is: 
       
         
           
           
               
               
           
         
         wherein PG is a suitable protecting group. 
       
     
     
         51 . The compound of  claim 47  wherein the compound is: 
       
         
           
           
               
               
           
         
         wherein —OR LG  is a suitable leaving group. 
       
     
     
         52 . The compound of  claim 47  wherein the compound is: 
       
         
           
           
               
               
           
         
         wherein PG is a suitable protecting group. 
       
     
     
         53 . The compound of  claim 47  wherein the compound is: 
       
         
           
           
               
               
           
         
         wherein —OR LG  is a suitable leaving group. 
       
     
     
         54 . The compound of  claim 47 , wherein —OR LG  is a C 1-6  aliphatic alkoxy group. 
     
     
         55 . The compound of  claim 47 , wherein PG is a Boc group. 
     
     
         56 . The compound of  claim 47  wherein the compound is: 
       
         
           
           
               
               
           
         
       
     
     
         57 . The compound of  claim 47  wherein the compound is:

Join the waitlist — get patent alerts

Track US2017114039A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.